mirabegron 25 mg

DRUG5 trials

Conditions

AsthmaChronic Orthostatic IntoleranceCirrhosisPostural Orthostatic Tachycardia SyndromeSyncopeTreatment of Non-monosymptomatic Nocturnal EnuresisUreteral Stent-Related SymptomUrinary Bladder Diseases

Phase 2

Using Mirabegron to Increase BP in Patients With POTS

CompletedNCT06133075

Cedars-Sinai Medical CenterChronic Orthostatic Intolerance, Postural Orthostatic Tachycardia Syndrome, Syncope

Start: 2023-12-22End: 2025-07-25Updated: 2026-04-08

Phase 3

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

CompletedNCT01908829

Astellas Pharma Europe Ltd.Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases

Start: 2013-07-10End: 2014-11-25Updated: 2024-10-31

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

RecruitingNCT06803030

Bir HospitalUreteral Stent-Related Symptom

Start: 2025-08-30End: 2026-12-31Target: 189Updated: 2025-09-08

Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children

Active, not recruitingNCT07398261

Menoufia UniversityTreatment of Non-monosymptomatic Nocturnal Enuresis

Start: 2023-08-28End: 2026-11-01Target: 151Updated: 2026-02-09

Phase 4

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

CompletedNCT07533565

Kafrelsheikh UniversityAsthma, Cirrhosis

Start: 2024-07-01End: 2025-10-01Updated: 2026-04-16

Related Papers

PD36-02 MIRABEGRON ADD-ON TREATMENT TO SOLIFENACIN IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS: A RESPONDER ANALYSIS OF A RANDOMIZED, DOUBLE BLIND, PHASE 3B STUDY

The Journal of Urology2016-03-28

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)